<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01753037</url>
  </required_header>
  <id_info>
    <org_study_id>Mayo-06-004680</org_study_id>
    <nct_id>NCT01753037</nct_id>
  </id_info>
  <brief_title>Effects of Androgen Administration on Inflammation in Normal Women</brief_title>
  <official_title>Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that DHEA administration to increase male hormone in healthy
      normal-weight young women to levels present in women with Polycystic Ovary Syndrome will
      cause an inflammatory response in white blood cells in the fasting state, and in response to
      glucose ingestion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nuclear factor kappa B (NFkappaB) activation</measure>
    <time_frame>0 and 2 hours after glucose ingestion</time_frame>
    <description>White blood cell NFkappaB activation will be assessed in response to glucose ingestion before and after 5 days of DHEA or placebo administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>0 and 5 days after DHEA or placebo</time_frame>
    <description>Insulin sensitivity derived from an oral glucose tolerance test (OGTT) will be assessed before and after 5 days of DHEA or placebo administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hyperandrogenism</condition>
  <arm_group>
    <arm_group_label>DHEA Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of a capsule containing 130 mg of dehydroepiandrosterone (DHEA) for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of an identical capsule containing placebo for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dehydroepiandrosterone (DHEA)</intervention_name>
    <description>DHEA 130 mg administered orally for 5 days.</description>
    <arm_group_label>DHEA Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acceptable health based on interview, medical history, physical examination and lab
             tests

          -  Ability to comply with requirements of the study

          -  Ability and willingness to provide signed, witnessed informed consent

          -  Between the ages of 18-40 years

          -  Body mass index between 18 and 25

          -  Normal regular monthly periods

          -  No clinical evidence of androgen excess

          -  No evidence of polycystic ovaries on ultrasound

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Clinically significant pulmonary, cardiac, renal, hepatic, neurologic, psychiatric,
             infectious and malignant disease

          -  High blood pressure

          -  Current or recent (within 30 days prior to study entry) use of any drugs known or
             suspected to affect reproductive function including oral contraceptives, metformin,
             gonadotropin releasing hormone agonists, or anti-androgens (spironolactone, flutamide,
             etc.)

          -  Use of medications that have an adverse drug interaction with DHEA therapy including
             antipsychotics, phenothiazines, lithium, selective serotonin reuptake inhibitors,
             triazolam, estrogen or testosterone formulations

          -  Known hypersensitivity to DHEA

          -  Two first-degree relatives with breast cancer or ovarian cancer

          -  Documented or suspected history of recent (within 1 year) illicit drug abuse or
             alcoholism

          -  Tobacco smoking

          -  Ingestion of any investigational drugs within 4 weeks prior to study onset

          -  Pregnancy or lactation (less than or equal to 6 weeks postpartum)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Gonz√°lez, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2012</study_first_submitted>
  <study_first_submitted_qc>December 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2012</study_first_posted>
  <last_update_submitted>November 14, 2013</last_update_submitted>
  <last_update_submitted_qc>November 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Frank Gonzalez</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Hyperandrogenism</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Hyperandrogenism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Dehydroepiandrosterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

